Benfield P, Ward A, Clark B G, Jue S G
ADIS Drug Information Services, Auckland.
Drugs. 1988 Jun;35(6):670-84. doi: 10.2165/00003495-198835060-00004.
Bromperidol is a close structural analogue of haloperidol. Both agents possess similar pharmacodynamic properties which are consistent with central antidopaminergic activity. The available clinical data from non-comparative and comparative trials have shown that bromperidol possesses antipsychotic activity. Its overall efficacy was slightly greater than chlorpromazine and perphenazine, and similar to or slightly better than haloperidol in a small number of comparative studies. Bromperidol frequently displayed a faster onset of action than these comparative agents and there have been reports of bromperidol causing an activating effect. However, extrapyramidal side effects occurred with similar frequency and severity after bromperidol compared with the 3 reference drugs. Data from additional controlled clinical trials are required to confirm the comparative antipsychotic efficacy of bromperidol and to assess whether it possesses any advantages in certain sub-types of schizophrenia.
溴哌利多是氟哌啶醇的紧密结构类似物。这两种药物具有相似的药效学特性，与中枢抗多巴胺能活性一致。来自非对照试验和对照试验的现有临床数据表明，溴哌利多具有抗精神病活性。在少数对照研究中，其总体疗效略高于氯丙嗪和奋乃静，与氟哌啶醇相似或略优于氟哌啶醇。溴哌利多的起效时间通常比这些对照药物更快，并且有报道称溴哌利多会产生激活作用。然而，与三种参比药物相比，溴哌利多后锥体外系副作用的发生频率和严重程度相似。需要更多对照临床试验的数据来证实溴哌利多的相对抗精神病疗效，并评估它在某些精神分裂症亚型中是否具有任何优势。
